1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
DongKoo Bio & Pharm Co. Ltd.

DongKoo Bio & Pharm Co. Ltd.

KKRX:006620
3,300.00
KRW
-50.00
(-1.49%)
1,207.37EPS
3.07P/E
101.41BMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4,328.08
4,995.47
4,564.08
3,739.91
4,381.69
1,639.84
5,489.6
7,016.57
7,815.49
9,184.62
8,974.24
8,924.05
Basic EPS, GAAP
217
624
493.91
163
528.33
107.67
330
238
428
75
1,859
1,220.25
Free Cash Flow per Basic Share
243.79
344.6
392.11
-247.89
47.92
23.89
439.73
206.68
-448.59
-299.2
-914.84
-60.01
Dividend per Share
- -
- -
- -
- -
- -
11.11
33.36
100.89
110.09
122.05
120
- -
Book Value per Share
111.9
967.29
1,656.17
2,509.16
3,027.49
3,345.63
3,570.78
3,696.33
3,998.84
3,895.1
5,609.85
5,255.05
Tangible Book Value per Share
55.53
923.31
1,613.39
2,447.97
2,956.76
3,272.08
3,462.08
3,370.16
3,603.92
3,408.02
5,302.08
4,950.07
Basic Weighted Avg Shares
19
17
22
28
29
85
28
28
28
27
27
27
Sales/Revenue/Turnover
80,369
87,363
101,124
104,837
125,235
139,216
155,149
194,988
215,686
249,275
242,688
241,434
Operating Margin (%)
9.94
12.11
13.18
5.43
5.16
5.47
5.25
8.74
6.78
5.09
3.81
0.14
Depreciation Expense
1,863
2,153
2,207
2,267
3,633
4,506
5,054
5,632
6,028
7,274
8,919
8,277
Net Income, GAAP
4,030
10,913
10,943
4,569
15,101
9,140
9,327
6,614
11,812
2,036
50,272
33,013
Effective Tax Rate (%)
19.78
- -
16.82
14.12
17.22
11.26
17.71
16.44
19.89
47.87
18.3
23.42
Profit Margin (%)
5.01
12.49
10.82
4.36
12.06
6.57
6.01
3.39
5.48
0.82
20.71
13.67
Working Capital
-26,661
-9,095
9,938
30,191
33,556
31,844
23,811
21,374
15,046
-8,009
-11,173
-13,396
LT Debt
5,950
1,248
2,412
1,925
5,499
5,219
770
754
2,461
11,084
22,986
23,926
Total Equity
2,550
22,045
37,745
72,098
85,652
94,653
100,124
102,106
110,445
105,448
152,159
142,576
Return on Invested Capital (%)
- -
- -
24.01
7.27
5.66
6.04
5.56
10.87
7.99
3.78
3.18
0.11
Return on Capital (%)
- -
- -
24.2
7.1
15.98
8.4
7.96
5.74
9.1
2.07
22.51
15.23
Return on Common Equity (%)
- -
88.74
36.61
8.32
19.14
10.14
9.58
6.54
11.12
1.89
39.12
25.98

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
105,795
105,484
98,703
LT Borrowings
22,852
22,279
23,200
LT Finance Leases
134
344
726
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
147,920
136,833
101,408

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
126,301
112,744
117,550
Cash, Cash Equivalents & STI
35,165
41,287
51,011
Accounts Receivable, Net
19,343
22,709
22,534
Inventories
49,996
43,749
36,242
Total Current Liabilities
137,473
147,334
130,946
Payables & Accruals
- -
- -
- -
ST Debt
105,795
105,484
98,703
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
101.17%
11.14%
44.3%
Free Cash Flow
13.94%
62.75%
204.66%
Net Income, GAAP
264.24%
467.7%
2,369.74%
Sales/Revenue/Turnover
11.94%
12.14%
-2.64%
Total Cash Common Dividend
- -
- -
-2.04%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
64,208
61,308
66,185
57,575
249,275
2025
58,676
60,117
62,020
61,875
242,688
2026
58,064
59,475
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
159
83
131
-304.28
75
2025
-25
418
-59.72
1,526.27
1,859
2026
-21.35
-224
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
122.05
2025
- -
- -
- -
- -
120
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yong-Joon Cho
Full Time Employees
440
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
Seoul South Korea
IPO Date
Feb 2, 2018
Website
dongkoo.com
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
DongKoo Bio & Pharm Co., Ltd. is a South Korea-based pharmaceutical and biotechnology company specializing in the development, manufacture, and commercialization of prescription drugs, medical devices, cosmeceuticals, and contract development and manufacturing organization (CDMO) services. Founded in 1970 and headquartered in Seoul, South Korea, the company operates specialized manufacturing and research facilities in Hwaseong, Gyeonggi-do, serving domestic and international markets across Asia, Latin America, and emerging global territories. The company maintains leading domestic prescription market positions in dermatology and urology while expanding into chronic disease therapies. Its primary products and services include dermatological therapeutics encompassing topical corticosteroids, antihistamines, antifungal formulations, and treatments for atopic dermatitis, eczema, and psoriasis; urological pharmaceuticals comprising therapies for benign prostatic hyperplasia, erectile dysfunction, and overactive bladder; internal medicine medications covering cardiovascular, gastrointestinal, respiratory, endocrine, and musculoskeletal disorders; medical devices and regenerative medicine systems centered on SmartX, an autologous adipose-derived stromal vascular fraction (SVF) extraction kit used in aesthetic and therapeutic procedures; cosmeceuticals marketed under the Cell Bloom brand featuring stem cell culture medium technologies for anti-aging and skin barrier recovery; and comprehensive CDMO services offering formulation development, clinical batch production, and commercial manufacturing for soft capsules, tablets, and topical products. In recent strategic developments, DongKoo Bio & Pharm has accelerated its open innovation strategy through targeted equity investments and co-development alliances with emerging biopharmaceutical and digital healthcare ventures, including peptide drug developer D&D Pharmatech, advanced cell therapy firms, and AI medical diagnostics providers. The company has simultaneously broadened its global presence by entering strategic export and joint production initiatives across Southeast Asian markets, while advancing multi-target combination drug candidates for metabolic and urological conditions to strengthen its long-term revenue pipeline.